Literature DB >> 7357791

Lidocaine plasma protein binding.

P A Routledge, A Barchowsky, T D Bjornsson, B B Kitchell, D G Shand.   

Abstract

The percent of unbound lidocaine in the plasma of 24 healthy subjects was measured by equilibrium dialysis after addition of 3 microgram/ml C14 lidocaine hydrochloride. The percentage of unbound lidocaine varied from 19.9 to 38.8 (30.2 +/- 5, mean +/- SD) was inversely related to the concentration of alpha 1-acid glycoprotein (AAG) in the plasma (r = -0.931, p less than 0.001). The binding ratio (number of moles bound divided by number of moles unbound) of lidocaine was directly related to the plasma AAG concentration (r = 0.960, p less than 0.001). The binding ratio of lidocaine in solutions containing AAG but no albumin, prepared from the plasma of subjects in the study, was also directly related to the concentration of this acute-phase protein (r = 0.909, p less than 0.001). Human serum albumin solution (4 gm/100 ml) bound lidocaine to the extent of 20% under the same conditions. There was no relationship between the binding ratio of lidocaine and the albumin concentration in the plasma of the 24 subjects. In 7 normal subjects variation in AAG between 2 samples collected at least 1 mo apart was associated with a concomitant change in plasma lidocaine binding (r = 0.943, p less than 0.01). Thus even in normal subjects there is considerable interindividual and intraindividual variation in lidocaine binding, and measurements of AAG concentration in plasma may be a useful predictor of the extent of lidocaine plasma binding.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7357791     DOI: 10.1038/clpt.1980.46

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  42 in total

Review 1.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 3.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

4.  Protein binding of cocaine in human serum.

Authors:  D J Edwards; S K Bowles
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

5.  Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein.

Authors:  F Brée; G Houin; J Barré; J L Moretti; V Wirquin; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

6.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

7.  Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.

Authors:  G T Tucker; N D Bax; M S Lennard; S Al-Asady; H S Bharaj; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of epidural and spinal anaesthesia.

Authors:  A G Burm
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

9.  alpha 1-Acid glycoprotein and plasma lidocaine binding.

Authors:  D G Shand
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 10.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.